Patents by Inventor Chintamani ATREYA

Chintamani ATREYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inactivation of pathogens in ex vivo blood products in storage bags using visible light
    Patent number: 11951217
    Abstract: Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 9, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Strathelyde
    Inventors: Chintamani Atreya, Michelle Maclean, John G. Anderson, Scott J. MacGregor
  • INACTIVATION OF PATHOGENS IN EX VIVO BLOOD PRODUCTS IN STORAGE BAGS USING VISIBLE LIGHT
    Publication number: 20220273834
    Abstract: Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
    Type: Application
    Filed: May 20, 2022
    Publication date: September 1, 2022
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The University of Strathclyde
    Inventors: Chintamani Atreya, Michelle Maclean, John G. Anderson, Scott J. MacGregor
  • INACTIVATION OF PATHOGENS IN EX VIVO BLOOD PRODUCTS IN STORAGE BAGS USING VISIBLE LIGHT
    Publication number: 20190070323
    Abstract: Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 7, 2019
    Applicants: The US of America, as represented by the Secretary Dept. of Health and Human Servics, The University of Strathclyde
    Inventors: Chintamani Atreya, Michelle Maclean, John G. Anderson, Scott J. MacGregor
  • Anti-microbial activity of synthetic peptides
    Patent number: 9243036
    Abstract: Isolated synthetic peptides are disclosed that have anti-microbial activity against E. coli and P. aeruginosa. These isolated peptides can be used as anti-viral agents. The use of these peptides to treat infections with E. coli and P. aeruginosa and viruses are disclosed. The disclosed peptides are also of use for treating a biofilm, such as a biofilm on a medical device.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 26, 2016
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Chintamani Atreya, Shilpakala Sainath Rao, Krishna Mohan V. Ketha
  • ANTI-MICROBIAL ACTIVITY OF SYNTHETIC PEPTIDES
    Publication number: 20150322113
    Abstract: Isolated synthetic peptides are disclosed that have anti-microbial activity against E. coli and P. aeruginosa. These isolated peptides can be used as anti-viral agents. The use of these peptides to treat infections with E. coli and P. aeruginosa and viruses are disclosed. The disclosed peptides are also of use for treating a biofilm, such as a biofilm on a medical device.
    Type: Application
    Filed: August 15, 2012
    Publication date: November 12, 2015
    Inventors: Chintamani ATREYA, Shilpakala Sainath RAO, Krishna Mohan V. RAO